Coronavirus: they approved the trial of a new vaccine in the country and are looking for 5,000 volunteers

The National Administration of Drugs, Foods and Medical Technology (Anmat) today approved the Phase III clinical trial of the Covid-19 vaccine from Canadian biopharmaceutical company Medicago. In Argentina, 5,000 volunteers will be solicited to obtain data on the efficacy and safety of the product, which will be supplemented by others to be collected in Mexico, Peru, Colombia, the United States and Canada. – even, among other countries.

As stated by the company in a statement released this morning, the company “applies a different technology than that used by most pharmaceutical companies and is based on the use of living plants as bioreactors to reproduce a non-infectious particle which mimics the target virus, but without the use of live viruses. It is known as virus-like particles (virus like particle, VLP) “. Medicago vaccine requires two applications three weeks apart. Interested parties should register at www.mautalenvacunas.com.

This new trial joins others that are under the analysis of the Argentinian regulatory body (among them, BriLife, developed in Israel, with phase II still pending publication) and some that have already been successfully conducted, like the vaccine. -BioNTech, the North American-Belgian from Janssen (Johnson and Johnson) and the Chinese from Sinopharm, Cansino (one dose), which was coordinated by the host Foundation.

Developing news

THE NATION